CN114728063B - 用抗ox40抗体和多重激酶抑制剂治疗癌症 - Google Patents

用抗ox40抗体和多重激酶抑制剂治疗癌症 Download PDF

Info

Publication number
CN114728063B
CN114728063B CN202080080793.6A CN202080080793A CN114728063B CN 114728063 B CN114728063 B CN 114728063B CN 202080080793 A CN202080080793 A CN 202080080793A CN 114728063 B CN114728063 B CN 114728063B
Authority
CN
China
Prior art keywords
seq
variable region
chain variable
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080080793.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728063A (zh
Inventor
蒋蓓蓓
刘晔
宋晓敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN114728063A publication Critical patent/CN114728063A/zh
Application granted granted Critical
Publication of CN114728063B publication Critical patent/CN114728063B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080080793.6A 2019-11-21 2020-11-19 用抗ox40抗体和多重激酶抑制剂治疗癌症 Active CN114728063B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120054 2019-11-21
CN2019120054 2019-11-21
PCT/CN2020/130059 WO2021098769A1 (en) 2019-11-21 2020-11-19 Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors

Publications (2)

Publication Number Publication Date
CN114728063A CN114728063A (zh) 2022-07-08
CN114728063B true CN114728063B (zh) 2024-06-14

Family

ID=75981033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080793.6A Active CN114728063B (zh) 2019-11-21 2020-11-19 用抗ox40抗体和多重激酶抑制剂治疗癌症

Country Status (5)

Country Link
US (1) US20230022859A1 (https=)
EP (1) EP4061421A4 (https=)
JP (1) JP2023503229A (https=)
CN (1) CN114728063B (https=)
WO (1) WO2021098769A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935A (zh) * 2018-05-23 2021-03-26 百济神州有限公司 抗ox40抗体和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
CN102010407A (zh) * 2010-11-16 2011-04-13 上海科胜药物研发有限公司 一种合成达沙替尼的新方法
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
KR20180011839A (ko) * 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
MX2020012081A (es) * 2018-05-11 2021-04-28 Wuxi Biologics Shanghai Co Ltd Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935A (zh) * 2018-05-23 2021-03-26 百济神州有限公司 抗ox40抗体和使用方法

Also Published As

Publication number Publication date
EP4061421A1 (en) 2022-09-28
EP4061421A4 (en) 2024-05-15
WO2021098769A1 (en) 2021-05-27
CN114728063A (zh) 2022-07-08
US20230022859A1 (en) 2023-01-26
JP2023503229A (ja) 2023-01-27

Similar Documents

Publication Publication Date Title
CN112566935B (zh) 抗ox40抗体和使用方法
JP2023503396A (ja) 抗ｐｄ１抗体又は抗ｐｄｌ１抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
US20230002500A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
US20230011916A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
WO2021098748A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
CA3100766C (en) Anti-ox40 antibodies and methods of use
HK40076999A (en) Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
HK40076665A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40076664A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
EA046633B1 (ru) Способы лечения рака с применением антител к ox40 в комбинации с антителами к tigit
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
EA047307B1 (ru) Способы лечения рака с применением антител к ox40 в комбинации с антителами к tim3
HK40050839A (en) Anti-ox40 antibodies and methods of use
EA045547B1 (ru) Антитела к ox40 и способы применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076999

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant